CXCR
信号通路图
研究领域
抑制剂选择性比较
特异性亚型抑制剂
CXCR产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S3951 |
Tannic acidTannic acid, a polyphenolic compound, is a CXCL12/CXCR4 inhibitor with antiangiogenic, anti-inflammatory and antitumor activity. |
||
| S8640 |
Reparixin (Repertaxin)Reparixin (Repertaxin)是人类和大鼠CXCR1/R2激活的抑制剂。它还可以抑制人类CXCL8受体的激活。 |
||
| S3013 |
Plerixafor 8HCl (AMD3100 8HCl)Plerixafor 8HCl (AMD3100 8HCl)是Plerixafor的盐酸盐，是CXCR4趋化因子受体拮抗剂，作用于CXCR4和CXCL12介导调节的趋化性， IC50分别为44 nM和5.7 nM。 |
BLI of NSG mice engrafted with BV173, treated with no therapy (control), plerixafor: 1 mg/kg IP daily, ESKM 100 ug twice weekly, and a combination of ESKM and plerixafor. (A) Logarithmic plot of BLI of leukemia growth measured weekly. Error bars are 5-95% confidence intervals. There was a small but not significant difference between ESKM and combination treated group. (B) End of therapy (day 34) BLI.
|
|
| S8030 |
Plerixafor (AMD3100)Plerixafor (AMD3100)是一种趋化因子受体拮抗剂，作用于CXCR4和CXCL12介导的趋化性，无细胞试验中IC50分别为44 nM和5.7 nM。 |
BLI of NSG mice engrafted with BV173, treated with no therapy (control), plerixafor: 1 mg/kg IP daily, ESKM 100 ug twice weekly, and a combination of ESKM and plerixafor. (A) Logarithmic plot of BLI of leukemia growth measured weekly. Error bars are 5-95% confidence intervals. There was a small but not significant difference between ESKM and combination treated group. (B) End of therapy (day 34) BLI.
|
|
| S2912 |
WZ811WZ811是一种高效的，竞争性的CXCR4拮抗剂，EC50为0.3 nM。 |
Gelatin degradation by COR-L23 (f) cells treated with 1 μM PF-573228 and 1 μM WZ811. Histograms showing percentages of degraded gelatin areas relative to the cell volume for each cell line are presented together with representative images. Merged channels show fluorescent gelatin (green), actin (red) and nuclei (blue) staining; dark areas represent spots of degraded gelatin. Scale bar = 100 μm. |
|
| S2879 |
AMD3465 hexahydrobromideAMD3465是一种单一大环类CXCR4的拮抗剂。 |
||
| S8813New |
LIT-927LIT-927是一种新型的CXCL12中性配体，抑制CXCL2和德州红染料的结合，Ki值为267 nM。它对CXCL12具有高选择性。 |
||
| S7651 |
SB225002SB225002是一种强效的选择性CXCR2拮抗剂，抑制白介素IL-8与CXCR2的结合，IC50为22 nM，选择性比其它测试的7-TMRs高150多倍。 |
SB225002 could inhibited h-JBMMSCs chemotaxis in both the co-culture and the monoculture transwell systems (n = 3; *P < 0.05). |
|
| S8309 |
ATI-2341ATI-2341，一种靶向C-X-C 4型趋化因子受体（CXCR4）的肽段，是一个变构受体激动剂，能够激活异源三聚体G蛋白（Gi）、抑制cAMP生成以及诱导钙动员。 |
||
| S8869New |
UNBS5162UNBS5162是CXCL趋化因子表达的拮抗剂，在一系列人类癌细胞包括恶性胶质瘤(Hs683和U373MG)、结肠直肠癌（HCT-15和LoVo）、乳腺癌细胞（MCF-7）中具有细胞毒性，IC50范围为0.5-5 μM。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S3951 |
Tannic acidTannic acid, a polyphenolic compound, is a CXCL12/CXCR4 inhibitor with antiangiogenic, anti-inflammatory and antitumor activity. |
||
| S8640 |
Reparixin (Repertaxin)Reparixin (Repertaxin)是人类和大鼠CXCR1/R2激活的抑制剂。它还可以抑制人类CXCL8受体的激活。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S3013 |
Plerixafor 8HCl (AMD3100 8HCl)Plerixafor 8HCl (AMD3100 8HCl)是Plerixafor的盐酸盐，是CXCR4趋化因子受体拮抗剂，作用于CXCR4和CXCL12介导调节的趋化性， IC50分别为44 nM和5.7 nM。 |
BLI of NSG mice engrafted with BV173, treated with no therapy (control), plerixafor: 1 mg/kg IP daily, ESKM 100 ug twice weekly, and a combination of ESKM and plerixafor. (A) Logarithmic plot of BLI of leukemia growth measured weekly. Error bars are 5-95% confidence intervals. There was a small but not significant difference between ESKM and combination treated group. (B) End of therapy (day 34) BLI.
|
|
| S8030 |
Plerixafor (AMD3100)Plerixafor (AMD3100)是一种趋化因子受体拮抗剂，作用于CXCR4和CXCL12介导的趋化性，无细胞试验中IC50分别为44 nM和5.7 nM。 |
BLI of NSG mice engrafted with BV173, treated with no therapy (control), plerixafor: 1 mg/kg IP daily, ESKM 100 ug twice weekly, and a combination of ESKM and plerixafor. (A) Logarithmic plot of BLI of leukemia growth measured weekly. Error bars are 5-95% confidence intervals. There was a small but not significant difference between ESKM and combination treated group. (B) End of therapy (day 34) BLI.
|
|
| S2912 |
WZ811WZ811是一种高效的，竞争性的CXCR4拮抗剂，EC50为0.3 nM。 |
Gelatin degradation by COR-L23 (f) cells treated with 1 μM PF-573228 and 1 μM WZ811. Histograms showing percentages of degraded gelatin areas relative to the cell volume for each cell line are presented together with representative images. Merged channels show fluorescent gelatin (green), actin (red) and nuclei (blue) staining; dark areas represent spots of degraded gelatin. Scale bar = 100 μm. |
|
| S2879 |
AMD3465 hexahydrobromideAMD3465是一种单一大环类CXCR4的拮抗剂。 |
||
| S8813New |
LIT-927LIT-927是一种新型的CXCL12中性配体，抑制CXCL2和德州红染料的结合，Ki值为267 nM。它对CXCL12具有高选择性。 |
||
| S7651 |
SB225002SB225002是一种强效的选择性CXCR2拮抗剂，抑制白介素IL-8与CXCR2的结合，IC50为22 nM，选择性比其它测试的7-TMRs高150多倍。 |
SB225002 could inhibited h-JBMMSCs chemotaxis in both the co-culture and the monoculture transwell systems (n = 3; *P < 0.05). |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S8309 |
ATI-2341ATI-2341，一种靶向C-X-C 4型趋化因子受体（CXCR4）的肽段，是一个变构受体激动剂，能够激活异源三聚体G蛋白（Gi）、抑制cAMP生成以及诱导钙动员。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S8869New |
UNBS5162UNBS5162是CXCL趋化因子表达的拮抗剂，在一系列人类癌细胞包括恶性胶质瘤(Hs683和U373MG)、结肠直肠癌（HCT-15和LoVo）、乳腺癌细胞（MCF-7）中具有细胞毒性，IC50范围为0.5-5 μM。 |
